TAVR for Aortic Valve Disease

Last updated: November 13, 2024
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Valve Disease

Treatment

transcatheter heart valve

Clinical Study ID

NCT05439863
NanjingValve Registry
  • Ages > 18
  • All Genders

Study Summary

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation

  2. Patients undergo transcatheter aortic valve replacement

Exclusion

Exclusion Criteria:

patients refuse the clinical follow-up

Study Design

Total Participants: 5000
Treatment Group(s): 1
Primary Treatment: transcatheter heart valve
Phase:
Study Start date:
July 01, 2022
Estimated Completion Date:
December 30, 2037

Connect with a study center

  • Nanjing First Hospital

    Nanjing, Jiangsu 210006
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.